Abstract
Streptozotocin is a nitrosourea with minimal activity against colorectal carcinoma when given by bolus administration. Continuous infusion (CI) streptozotocin has been reportedly less toxic. Twenty-six patients with widely advanced colorectal carcinoma (most heavily pretreated) received 1-3 courses of Streptozotocin by CI to determine efficacy. Two patients (8%) had an objective response. Although CI Streptozotocin is less toxic, it does not have substantial efficacy in colorectal cancer in previously treated patients with widespread metastases.
Get full access to this article
View all access options for this article.